# AOD-9604: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on AOD-9604 — the hGH-fragment fat-loss peptide that completed six human RCTs and largely failed to beat placebo. Strong safety data, a failed pivotal weight-loss trial, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
AOD-9604 is the rare fat-loss peptide that was *actually tested in humans* — six randomized placebo-controlled trials in 893 obese adults. The result inverts its reputation: **Grade A evidence that it is safe**, and Grade A evidence that at studied doses it does **not** deliver clinically meaningful weight loss (the pivotal 502-subject trial failed to beat placebo). Any positive fat-loss or joint-repair claim grades only C/D. It is not FDA-approved, is in 2026 compounding limbo, and is banned in sport.[1](https://peptidevox.com/#r1)[7](https://peptidevox.com/#r7)

AOD-9604 ("anti-obesity drug 9604," also coded LAT8881) is a 16-amino-acid synthetic analog of the lipolytic C-terminal tail of human growth hormone — hGH residues 177-191 plus an N-terminal tyrosine — engineered to stimulate fat breakdown without the IGF-1, growth-promoting or diabetogenic effects of full hGH.[1](https://peptidevox.com/#r1) It is marketed as a "proven fat-loss peptide." Its own clinical record says otherwise. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. AOD-9604 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is AOD-9604 and how does it work?

AOD-9604 is the C-terminal fragment of human growth hormone spanning residues 177-191 (15 amino acids) with an added N-terminal tyrosine, giving a 16-residue peptide (Tyr-hGH 177-191) cyclized via a disulfide bond between its two cysteines and produced by solid-phase peptide synthesis.[2](https://peptidevox.com/#r2) The extra tyrosine distinguishes it from the closely related hGH 176-191 ("HGH Fragment 176-191"); both share the same purported lipolytic domain.[1](https://peptidevox.com/#r1) The compound was developed at Monash University and commercialized by Metabolic Pharmaceuticals in Australia.[3](https://peptidevox.com/#r3)

The proposed mechanism — graded C, preclinical and mechanistic — is that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis), in part by inhibiting acetyl-CoA carboxylase in hepatocytes and adipocytes and possibly by increasing repressed beta-3-adrenoceptor RNA expression in adipose tissue.[2](https://peptidevox.com/#r2) Critically, it does not stimulate IGF-1 production and is not a high-affinity GH-receptor agonist or antagonist — the fragment was specifically selected to dissociate the fat-metabolism action of GH from its anabolic and diabetogenic actions.[2](https://peptidevox.com/#r2) From a functional, root-cause standpoint the theory is attractive — restore a lipolytic signal suppressed in obesity without GH's metabolic downsides — but the human receptor target remains incompletely defined and the beta-3 mechanism is inferred from animal work, not confirmed in human metabolic studies. More recent work re-frames the molecule (as LAT8881) as a lanthionine synthetase C-like protein (LANCL) activator, a distinct preclinical hypothesis explored for cartilage, neuropathic pain and influenza.[14](https://peptidevox.com/#r14)

The pharmacokinetics explain why the original developers chose pills, not injections. AOD-9604 is rapidly cleared — an IV half-life of roughly 3 minutes in pigs versus about 21 minutes for full hGH — yet pig data showed an unusually high estimated oral bioavailability of about 40%, so the human program used oral capsules.[2](https://peptidevox.com/#r2) Preclinical no-observed-adverse-effect levels were at least 100 mg/kg/day oral in rats and 50 mg/kg/day in monkeys, supporting a wide safety margin.[2](https://peptidevox.com/#r2)

## What is the evidence by indication?

This is the central, often-glossed-over story. Unlike most peptides marketed for body composition, AOD-9604 ran a genuine clinical program — and that program is precisely why its efficacy narrative collapses.

  AOD-9604 evidence by indication

    IndicationBest evidenceGrade

    Obesity / weight loss (negative conclusion)6 randomized placebo-controlled trials, n=893; pivotal 502-subject trial failed to beat placeboA (negative)
    Obesity / weight loss (positive efficacy claim)Early small trials' modest ~2 kg signal; not replicated in the pivotal trialC-to-D
    Cartilage repair / osteoarthritisOne rabbit knee-OA study (intra-articular ± hyaluronic acid); no human trialsC (preclinical)
    Neuropathic pain / antiviral (as LAT8881)LANCL-activator candidate; in-vitro influenza work; no positive human dataC-to-D
    Safety / tolerabilityPooled 6-RCT analysis: profile "indistinguishable from placebo"A

The weight-loss program comprised six randomized, double-blind, placebo-controlled trials (2001-2006, n=893): two IV pilots, two oral pilots, and two oral Phase IIb efficacy trials.[1](https://peptidevox.com/#r1) In METAOD005 (12 weeks, ~300 obese adults), the 1 mg/day oral group lost on average about 2.6 to 2.8 kg versus roughly 0.8 kg on placebo — statistically significant in that trial, with a small improvement in glucose tolerance, and counter-intuitively higher doses were no better than 1 mg.[3](https://peptidevox.com/#r3) But METAOD006 (24 weeks, 502 obese adults, oral 0.25-1 mg/day with diet and exercise) — the pivotal, larger, longer trial — failed: weight loss did not separate from placebo once an intensive diet-and-exercise regimen was added, and IGF-1 changes were non-significant.[1](https://peptidevox.com/#r1) Metabolic Pharmaceuticals concluded the results "did not support the commercial viability of the drug as a treatment for obesity," discontinuing the program in 2007.[1](https://peptidevox.com/#r1) For context, even the best early signal (~2 kg over placebo) is dwarfed by approved therapies — orlistat (~3-4 kg) and GLP-1/GIP agonists such as semaglutide (~15%) and tirzepatide (~21% of body weight).[6](https://peptidevox.com/#r6)

The joint-health reputation rests almost entirely on one preclinical study: a collagenase-induced knee-osteoarthritis model in 32 New Zealand white rabbits, where weekly intra-articular AOD-9604, especially combined with hyaluronic acid, enhanced cartilage regeneration versus saline.[4](https://peptidevox.com/#r4) No human efficacy trial for cartilage or osteoarthritis has reported results, so any human joint-repair claim is extrapolation from a single rabbit study. The original positive rationale traces to mouse and in-vitro work showing increased fat oxidation and weight loss in obese mice.[Heffernan and colleagues (2001, PMID 11673763)](https://pubmed.ncbi.nlm.nih.gov/11673763/) — preclinical, not human.[5](https://peptidevox.com/#r5)

Proven vs hyped
Proven: that AOD-9604 is *safe*. Largely disproven: that it *works* for weight loss at studied doses, after the pivotal 502-subject trial failed to beat placebo. Its reputation as a "proven fat-loss peptide" is inverted by its own clinical record.[1](https://peptidevox.com/#r1)

## What doses appear in the literature?

Reported strictly as information, not a protocol. The clinical-trial program used oral capsules and IV infusions — not subcutaneous injection.[1](https://peptidevox.com/#r1) The IV pilots used 25-400 µg/kg single doses; the oral pilots used 9-54 mg single or daily doses for 7 days; the oral Phase IIb trials used 1-30 mg/day for 12 weeks (METAOD005) and 0.25-1 mg/day for 24 weeks (METAOD006), with the reported optimal weight-loss dose being 1 mg/day oral and no benefit above it.[1](https://peptidevox.com/#r1) The preclinical osteoarthritis work used intra-articular 0.25 mg with or without hyaluronic acid, weekly, in rabbits.[4](https://peptidevox.com/#r4) The subcutaneous ~250-500 µg/day "reconstitute lyophilized powder with bacteriostatic water" regimen circulating in the gray market is a wellness/clinic convention, not derived from the trial program — there are no human efficacy trials of subcutaneous AOD-9604.[1](https://peptidevox.com/#r1) Because the molecule has high oral bioavailability (~40%) and a very short half-life, the original developers deliberately chose the oral route.[2](https://peptidevox.com/#r2)

## How safe is AOD-9604?

Safety is AOD-9604's strongest data point. Across all six trials (n=893) the safety profile was described as "indistinguishable from placebo."[1](https://peptidevox.com/#r1) Common adverse events were mild-to-moderate headache, diarrhea, flatulence and nausea, with gastrointestinal events increasing at the high 54 mg dose.[1](https://peptidevox.com/#r1) There were no treatment-related serious adverse events or withdrawals; in METAOD005 five SAEs (including basal cell carcinoma, melanoma and breast cancer) were judged unrelated to treatment, and in METAOD006 SAEs were distributed similarly across placebo and active groups.[1](https://peptidevox.com/#r1) IGF-1 showed no clinically significant change at any dose, oral glucose tolerance was unchanged with a favorable trend in impaired-glucose-tolerance subjects, and anti-AOD-9604 antibodies were undetectable.[1](https://peptidevox.com/#r1)

Because the molecule does not raise IGF-1 and showed no proliferative signal in cell assays, the GH-class concern about tumor promotion is theoretically lower than with full hGH — but long-term human carcinogenicity data simply do not exist.[5](https://peptidevox.com/#r5) In practice the dominant real-world safety risk in 2026 is product, not molecule: gray-market "research-only" vials carry no guarantee of identity, purity, sterility or correct dose and are not pharmaceutical-grade.[11](https://peptidevox.com/#r11) Pregnancy, lactation, pediatrics and active malignancy are untested and should be avoided, and no formal drug-interaction studies exist.

## What is the FDA and WADA status in 2026?

AOD-9604 has never been FDA-approved for any indication, has no USP monograph, and is not an active ingredient in any approved drug — so it fails the baseline statutory criteria for pharmacy compounding.[9](https://peptidevox.com/#r9) The timeline is precise: in September 2023 the FDA placed AOD-9604 (with several other peptides) in 503A Category 2 ("may present significant safety risks"), barring its use in compounding; in September 2024, following litigation and a settlement, the FDA removed it from Category 2 because the nominators withdrew their nominations — explicitly not an approval; and at the December 4, 2024 PCAC meeting the committee voted against including it on the 503A bulks list.[10](https://peptidevox.com/#r10) In 2026 a political push (an HHS announcement on February 27, 2026) signaled intent to move roughly 14 Category-2 peptides, including AOD-9604, toward Category 1, with PCAC review slated for July 23-24, 2026. Commentators stress this is political intent, not a final FDA rule — it does not confer approval, validated dosing or proven benefit.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12) A self-affirmed industry-panel "Generally Recognized As Safe" (GRAS) food-ingredient determination also exists, but a GRAS self-determination is a far lower bar than drug approval and validates no therapeutic claim.[13](https://peptidevox.com/#r13)

For athletes the picture is unambiguous. AOD-9604 is explicitly named on the [WADA Prohibited List](https://www.wada-ama.org/en/prohibited-list) under S2.2 — Growth Hormone, its analogues and fragments ("growth hormone fragments, e.g. AOD-9604 and hGH 176-191") — prohibited at all times, in and out of competition, and also captured by S0.[7](https://peptidevox.com/#r7) It is detectable by anti-doping labs via a stable urinary metabolite and is banned by professional leagues such as MLB; any WADA-tested athlete should treat it as banned.[8](https://peptidevox.com/#r8)

**Bottom line.** AOD-9604 is the rare fat-loss peptide actually put to the human test — and the test is the point. Six RCTs establish, at Grade A confidence, that it is remarkably safe and that at studied oral doses it does not deliver clinically meaningful weight loss. What's proven is safety and a coherent (if unconfirmed) lipolytic mechanism; what's hyped is that it is an effective fat-loss agent. Regulatory facts here are current as of June 2026; the July 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date. As of 2026 it remains not FDA-approved, not legally compoundable, and banned in sport.

---
Source: https://peptidevox.com/peptide-encyclopedia/aod-9604
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt